المؤلفون: Lin M; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Breast and Urinary Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Luo T; Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Multi-Omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China., Jin Y; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Zhong X; Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.; Multi-Omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu, China., Zheng D; Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, China., Zeng C; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Guo Q; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China., Wu J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Key Laboratory of Breast Cancer in Shanghai, Shanghai, China., Shao ZM; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.; Key Laboratory of Breast Cancer in Shanghai, Shanghai, China., Hu X; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Breast and Urinary Oncology, Fudan University Shanghai Cancer Center, Shanghai, China., Yang W; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China., Zhang J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.

المصدر: Cancer [Cancer] 2024 Mar 15; Vol. 130 (6), pp. 851-862. Date of Electronic Publication: 2023 Nov 07.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/genetics , Breast Neoplasms*/therapy , Breast Neoplasms*/metabolism, Humans ; Female ; Receptor, ErbB-2/metabolism ; Cohort Studies ; China ; Prognosis ; Receptors, Progesterone/metabolism

مستخلص: Background: With the largest sample size to date, the authors' objective was to investigate the incidence of primary-to-metastatic human epidermal growth factor 2 (HER2) conversion and the predictors for such conversion. Moreover, no previous studies have evaluated the prognosis of patients who have negative HER2 expression (HER2-0) versus low HER2 expression (HER2-low) when HER2 status was assessed based on all recurrent/metastatic lesions.
Methods: The authors included 1299 patients who had available HER2 status of primary breast tumors and paired recurrent/metastatic lesions at Fudan University Shanghai Cancer Center and West China Hospital.
Results: In total, 370 patients (28.5%) experienced primary-to-metastatic HER2 conversion. Intrapatient intermetastasis spatial heterogeneity and temporal heterogeneity of HER2 were detected. When assessing HER2 based on recurrent/metastatic tumors, patients who had HER2-0 tumors had significantly shorter overall survival than those who had HER2-low tumors in the overall population and in the estrogen receptor (ER)-negative subgroup. However, when assessing HER2 based on primary tumors, there was no difference in overall survival between patients who had HER2-0 versus HER2-low tumors. Moreover, patients who had tumors that converted from HER2-0 to HER2-low had longer overall survival than those who had consistent HER2-0 status in the ER-negative subgroup. By combining four predictors (ER status, Ki67 index, biopsy site, and disease-free interval), the authors established the first prediction tool to estimate the probability of HER2-0 tumors converting to HER2-low/positive tumors.
Conclusions: Intrapatient primary-to-metastatic and intermetastatic HER2 heterogeneity were observed in this large-scale cohort study. When evaluating HER2 based on recurrent/metastatic tumors, an overall survival difference was observed between patients who had HER2-0 versus HER2-low, recurrent/metastatic breast tumors. The developed prediction tool might help clinicians screen out patients with primary HER2-0 tumors that have a high probability of HER2 status conversion and recommend them for re-biopsy, thus helping to screen out candidate patients for trastuzumab deruxtecan treatment.
(© 2023 American Cancer Society.)

المؤلفون: Patel R; Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA., Hovstadius M; Frank H. Netter School of Medicine, Quinnipiac University, Hamden, Connecticut, USA., Kier MW; Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA., Moshier EL; Division of Biostatistics, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Zimmerman BS; Northwell Cancer Institute, Riverhead, New York, USA., Cascetta K; Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA., Jaffer S; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Sparano JA; Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA., Tiersten A; Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, New York, USA.

المصدر: Cancer [Cancer] 2022 Oct; Vol. 128 (20), pp. 3602-3609. Date of Electronic Publication: 2022 Aug 10.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology , Receptors, Progesterone*/genetics , Receptors, Progesterone*/metabolism, Ki-67 Antigen/*metabolism, Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Female ; Gene Expression Profiling ; Hormones ; Humans ; Ki-67 Antigen/genetics ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Retrospective Studies

مستخلص: Background: The relationship between Ki67 assessed by immunohistochemistry (IHC) and the Oncotype DX Recurrence Score (RS) is unclear. The objective of this study was to determine the correlation between the 21-gene RS and IHC-measured Ki67 with the prognostic classification groups recommended by the International Ki67 Working Group (IKWG).
Methods: The authors performed a retrospective chart review of women who had hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative early breast cancer with zero to three positive lymph nodes and both Ki67 and the 21-gene RS performed at their institution from 2013 to 2021. Patients were categorized into low (≤5%), intermediate (6%-29%), and high Ki67 groups (≥30%) according to IKWG recommendations. Overall agreement and risk-stratified agreement between Ki67 and RS were assessed with the proportion of agreement and the κ statistic.
Results: The study included 525 patients with HR-positive breast cancer. Among the 49% of patients with intermediate Ki67 values of 6%-29%, the distribution of low (0-10), intermediate (11-25), and high RS (26-100) was 19%, 66%, and 15%, respectively. There was slight agreement (κ = 0.01-0.20) between Ki67 and RS (κ = 0.027) in the overall population, although this was not significant (p = .1985). There was fair agreement (κ = 0.21-0.40) between high Ki67 and RS values (κ = 0.280; p < .0001). A higher progesterone receptor percentage was associated with lower RS values (p > .0001) but not lower Ki67 values. A positive nodal status and a larger tumor size were associated with higher Ki67 values (p = .0059 and p < .0001) but not with RS.
Conclusions: In this group of patients selected to have a 21-gene RS, there was no significant correlation between Ki67 and RS in the overall population, and there was fair agreement between high Ki67 and high RS values.
Lay Summary: In patients with early-stage, hormone receptor-positive breast cancer, decisions on adjuvant chemotherapy are based on certain biological features of the cancer and genomic assays such as the Oncotype DX Recurrence Score (RS). The goal of this study was to determine the correlation between Ki67, a marker of proliferation, and the Oncotype DX RS, a 21-gene assay demonstrated to be predictive of an adjuvant chemotherapy benefit in patients with early-stage breast cancer. In 525 patients, the authors did not find a significant correlation between Ki67 and RS.
(© 2022 American Cancer Society.)

المؤلفون: Lashen AG; School of Medicine, University of Nottingham, Nottingham, UK., Toss MS; School of Medicine, University of Nottingham, Nottingham, UK., Rakha EA; School of Medicine, University of Nottingham, Nottingham, UK.

المصدر: Cancer [Cancer] 2023 Jul 01; Vol. 129 (13), pp. 2105. Date of Electronic Publication: 2023 Apr 27.

نوع المنشور: Letter; Comment

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*, Female ; Humans ; Receptors, Progesterone/metabolism ; Progesterone ; Receptor, ErbB-2/metabolism ; Biomarkers, Tumor/metabolism

المؤلفون: Lehrer S; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Rheinstein PH; Severn Health Solutions, Severna Park, Maryland, USA.

المصدر: Cancer [Cancer] 2023 Jul 01; Vol. 129 (13), pp. 2103-2104. Date of Electronic Publication: 2023 Apr 27.

نوع المنشور: Letter; Research Support, N.I.H., Extramural; Comment

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*, Female ; Humans ; Receptors, Progesterone/metabolism ; Progesterone ; Receptor, ErbB-2/metabolism ; Biomarkers, Tumor/metabolism

المؤلفون: Lashen AG; Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.; Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt., Toss MS; Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.; Department of Histopathology, Sheffield Teaching Hospitals Foundation NHS Trust, Sheffield, UK., Mongan NP; School of Veterinary Medicine and Sciences, University of Nottingham, Nottingham, UK.; Department of Pharmacology, Weill Cornell Medicine, New York, New York, USA., Green AR; Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.; Nottingham Breast Cancer Research Centre, University of Nottingham, Nottingham, UK., Rakha EA; Academic Unit for Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.; Department of Pathology, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt.; Department of Pathology, Hamad Medical Corporation, Doha, Qatar.

المصدر: Cancer [Cancer] 2023 Apr 15; Vol. 129 (8), pp. 1183-1194. Date of Electronic Publication: 2023 Jan 18.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology, Humans ; Female ; Receptors, Progesterone/metabolism ; Progesterone/therapeutic use ; Ki-67 Antigen/metabolism ; Receptors, Estrogen/metabolism ; Follow-Up Studies ; Receptor, ErbB-2/metabolism ; Prognosis ; Biomarkers, Tumor

مستخلص: Background: The routine assessment of progesterone receptor (PR) expression in breast cancer (BC) remains controversial. This study aimed to evaluate the role of PR expression in luminal BC, with emphasis on the definition of positivity and its prognostic significance as compared to Ki67 expression.
Methods: A large cohort (n = 1924) of estrogen receptor (ER)-positive/HER2-negative BC was included. PR was immunohistochemically (IHC) stained on full face sections and core needle biopsies (CNB) where the optimal scoring cutoff was evaluated. In addition, the association of PR with other clinicopathological factors, cellular proliferation, disease outcome, and response to adjuvant therapy were analyzed.
Results: Although several cutoffs showed prognostic significance, the optimal cutoff to categorize PR expression into two clinically distinct prognostic groups on CNB was 10%. PR negativity showed a significant association with features of aggressive tumor behavior and poor outcome. Multivariate analyses indicated that the association between PR negativity and poor outcome was independent of tumor grade, size, node stage, and Ki67. PR negativity showed independent association with shorter survival in patients who received endocrine therapy whereas Ki67did not.
Conclusion: PR IHC expression provides independent prognostic value superior to Ki67. Routine assessment of PR expression in BC using 10% cutoff in the clinical setting is recommended.
Plain Language Summary: In this study, we have established an optimal approach to determine the prognostic value of progesterone receptor expression in estrogen receptor-positive breast cancer patients. To do this, the levels of progesterone receptor were measured in a large cohort of estrogen receptor-positive breast cancer patients. We have refined the definition of progesterone receptor positivity in estrogen receptor-positive breast cancer. We show that progesterone receptor expression adds prognostic and predictive value of endocrine therapy in estrogen receptor-positive breast cancer patients, and our results show that the absence of progesterone receptor is associated with poorer outcomes independent of tumor grade, size, node stage, and Ki67 expression.
(© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)

المؤلفون: Neuman HB; Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA., Schumacher JR; Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.; University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA., Edge SB; Departments of Surgical Oncology and Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA., Ruddy KJ; Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA., Partridge AH; Department of Medical Oncology, Dana-Farber/Partners Cancer Care, Boston, Massachusetts, USA., Yu M; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin, USA., Vanness DJ; Department of Health Policy and Administration, Penn State College of Health and Human Development, Hershey, Pennsylvania, USA., Hanlon BM; Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison, Wisconsin, USA., Le-Rademacher JG; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA., Yang DY; Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA., Havlena J; Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA., Strand CA; Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, Minnesota, USA., Greenberg CC; Department of Surgery, Medical College of Georgia at Augusta University, Augusta, Georgia, USA.

المصدر: Cancer [Cancer] 2023 May 01; Vol. 129 (9), pp. 1351-1360. Date of Electronic Publication: 2023 Mar 06.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*/pathology, Humans ; Female ; Receptor, ErbB-2 ; Receptors, Estrogen ; Neoplasm Recurrence, Local/pathology ; Receptors, Progesterone

مستخلص: Background: Risk-stratified follow-up guidelines that account for the absolute risk and timing of recurrence may improve the quality and efficiency of breast cancer follow-up. The objective of this study was to assess the relationship of anatomic stage and receptor status with timing of the first recurrence for patients with local-regional breast cancer and generate risk-stratified follow-up recommendations.
Methods: The authors conducted a secondary analysis of 8007 patients with stage I-III breast cancer who enrolled in nine Alliance legacy clinical trials from 1997 to 2013 (ClinicalTrials.gov identifier NCT02171078). Patients who received standard-of-care therapy were included. Patients who were missing stage or receptor status were excluded. The primary outcome was days from the earliest treatment start date to the date of first recurrence. The primary explanatory variable was anatomic stage. The analysis was stratified by receptor type. Cox proportional-hazards regression models produced cumulative probabilities of recurrence. A dynamic programming algorithm approach was used to optimize the timing of follow-up intervals based on the timing of recurrence events.
Results: The time to first recurrence varied significantly between receptor types (p < .0001). Within each receptor type, stage influenced the time to recurrence (p < .0001). The risk of recurrence was highest and occurred earliest for estrogen receptor (ER)-negative/progesterone receptor (PR)-negative/Her2neu-negative tumors (stage III; 5-year probability of recurrence, 45.5%). The risk of recurrence was lower for ER-positive/PR-positive/Her2neu-positive tumors (stage III; 5-year probability of recurrence, 15.3%), with recurrences distributed over time. Model-generated follow-up recommendations by stage and receptor type were created.
Conclusions: This study supports considering both anatomic stage and receptor status in follow-up recommendations. The implementation of risk-stratified guidelines based on these data has the potential to improve the quality and efficiency of follow-up.
(© 2023 American Cancer Society.)

المؤلفون: Hendrikse CSE; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., van der Ploeg P; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., van de Kruis NMA; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands., Wilting JHC; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands., Oosterkamp F; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands., Theelen PMM; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands., Lok CAR; Department of Gynecology and Obstetrics, Antoni van Leeuwenhoek, Amsterdam, the Netherlands., de Hullu JA; Department of Gynecology and Obstetrics, Radboud University Medical Center, Nijmegen, the Netherlands., Smedts HPM; Department of Gynecology and Obstetrics, Amphia Hospital, Breda, the Netherlands., Vos MC; Department of Gynecology and Obstetrics, Elisabeth-Tweesteden Ziekenhuis, Tilburg, the Netherlands., Pijlman BM; Department of Gynecology and Obstetrics, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, the Netherlands., Kooreman LFS; Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, the Netherlands., Bulten J; Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands., Lentjes-Beer MHFM; Department of Pathology, Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, the Netherlands., Bosch SL; Department of Pathology, Eurofins PAMM, Eindhoven, the Netherlands., van de Stolpe A; Philips Molecular Pathway Dx, Philips Research, Eindhoven, the Netherlands., Lambrechts S; Department of Gynecology and Obstetrics, Maastricht University Medical Center, Maastricht, the Netherlands., Bekkers RLM; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Piek JMJ; Department of Gynecology and Obstetrics and Catharina Cancer Institute, Catharina Hospital, Eindhoven, the Netherlands.

المصدر: Cancer [Cancer] 2023 May 01; Vol. 129 (9), pp. 1361-1371. Date of Electronic Publication: 2023 Mar 03.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Receptors, Estrogen*/metabolism , Ovarian Neoplasms*, Female ; Humans ; Biomarkers, Tumor/metabolism ; Neoplasm Recurrence, Local/drug therapy ; Carcinoma, Ovarian Epithelial/drug therapy ; Signal Transduction ; Receptors, Progesterone/metabolism

مستخلص: Background: Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.
Methods: Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.
Results: Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.
Conclusions: Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS.
(© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.)

المؤلفون: Jones VC; Department of Surgery, Division of Breast Surgery, City of Hope, Duarte, California., Kruper L; Department of Surgery, City of Hope, Duarte, California., Mortimer J; Department of Medical Oncology, City of Hope, Duarte, California., Ashing KT; Department of Population Sciences, City of Hope, Duarte, California., Seewaldt VL; Department of Population Sciences, City of Hope, Duarte, California.

المصدر: Cancer [Cancer] 2022 Jul 15; Vol. 128 (14), pp. 2695-2697. Date of Electronic Publication: 2022 May 17.

نوع المنشور: Editorial; Comment

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms*, Female ; Humans ; Receptors, Estrogen ; Receptors, Progesterone

المؤلفون: Glas AS; Department of Surgical Oncology, University Hospital Groningen, Groningen, The Netherlands., Hollema H, Nap RE, Plukker JT

المصدر: Cancer [Cancer] 2002 Apr 15; Vol. 94 (8), pp. 2211-6.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Print ISSN: 0008-543X (Print) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Adenoma, Pleomorphic/*metabolism , Neoplasm Recurrence, Local/*metabolism , Nuclear Proteins/*metabolism , Parotid Neoplasms/*metabolism , Receptors, Estrogen/*metabolism , Receptors, Progesterone/*metabolism , Receptors, Somatomedin/*metabolism, Adenoma, Pleomorphic/pathology ; Adenoma, Pleomorphic/surgery ; Adolescent ; Adult ; Aged ; Antigens, Nuclear ; Child ; Female ; Humans ; Immunoenzyme Techniques ; Ki-67 Antigen/metabolism ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/surgery ; Parotid Gland/metabolism ; Parotid Neoplasms/pathology ; Parotid Neoplasms/surgery ; Progesterone/metabolism ; Prognosis

مستخلص: Background: Patients with recurrent pleomorphic adenomas of the parotid gland are difficult to manage without considerable risk of facial nerve injury. The prognostic significance of progesterone receptor (PR) and estrogen receptor (ER) reported in these adenomas was evaluated in patients with recurrent pleomorphic adenomas, comparing the results in a group of patients with primary adenomas without recurrences during 10 years of follow-up.
Methods: Paraffin embedded tumor samples from 52 patients with recurrent pleomorphic adenoma of the parotid gland were collected and stained immunohistochemically. Expression of PR, ER, Ki-67 antigen, and insulin-like growth factor receptor-1 (IGFR-1) was analyzed in resected samples of recurrent tumors and was compared with samples from a control group of patients with primary pleomorphic adenoma.
Results: A difference (P < 0.05) in the type of tumor was observed between the recurrent group (more cell-poor variants) and the control group. ER expression was low in both groups (19% and 17%, respectively), but immunoreactivity for ER was higher (48%) in normal parotid gland tissue. PR expression in the recurrent group (96%) was higher compared with PR expression in the control group (61%; P < 0.001). PR expression and IGFR-1 expression were correlated weakly (correlation coefficient = 0.660; P = 0.053) in the recurrent group. The expression of growth fraction (Ki-67 score) and IGFR-1 was similar in both groups but was more extensive compared with normal parotid gland tissue.
Conclusions: PR seems to be a prognostic factor in recurrent pleomorphic adenoma of the parotid gland. The PR pathway can be considered a potential target for hormone treatment in patients with these recurrent adenomas.
(Copyright 2002 American Cancer Society.)

المؤلفون: Pujol P; Service de Biologie Cellulaire, Centre Hospitalier Universitaire de Montpellier et U540 Inserm, Montpellier, France. p-pujol@chu-montpellier.fr, Daures JP, Brouillet JP, Chang S, Rouanet P, Bringer J, Grenier J, Maudelonde T

المصدر: Cancer [Cancer] 2001 May 15; Vol. 91 (10), pp. 1854-61.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print Cited Medium: Print ISSN: 0008-543X (Print) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Premenopause*, Breast Neoplasms/*blood , Estradiol/*blood , Follicle Stimulating Hormone/*blood , Luteinizing Hormone/*blood , Progesterone/*blood, Breast Neoplasms/mortality ; Breast Neoplasms/surgery ; Cathepsin D/metabolism ; Female ; Humans ; Menstrual Cycle ; Multivariate Analysis ; Prognosis ; Prospective Studies ; Receptors, Estrogen/metabolism ; Receptors, Progesterone/metabolism ; Survival Rate ; Time Factors

مستخلص: Background: Despite numerous studies, the influence of timing at surgery in relation to the menstrual cycle on the prognosis of breast carcinoma is still controversial. Most studies are retrospective, and the reliability of the menstrual history data is limited by the lack of hormonal assessment at the time of surgery. The authors prospectively studied the influence of the menstrual cycle phase as determined by circulating hormones at the time of surgery on the outcome of breast carcinoma.
Methods: A population of 360 premenopausal women with nonmetastatic breast carcinoma operated on from 1992 to 1995 was analyzed. Serum estradiol, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels were assayed the day of surgery to define the menstrual cycle phase (follicular, n = 186; ovulatory, n = 24; luteal, n = 150). The mean follow-up was 48 months.
Results: There were no relations between the menstrual phase at surgery and tumor size, cathepsin D level, Scarff-Bloom-Richardson grade, Pg receptor (PgR), and the number of positive lymph nodes. The mean estrogen receptor level was higher during the follicular phase than in the ovulatory and luteal phases (P < 0.02). Univariate analysis of recurrence free survival (RFS) and overall survival (OS) showed no relations with the menstrual phase or the level of estradiol and progesterone at the time of surgery. High LH or FSH levels (above the medians) were associated with shorter RFS (P = 0.02 and P = 0.04, respectively) or OS (P < or = 0.01 and P = 0.01, respectively). In multivariate analysis, lymph node status, PgR status and LH level were the most significant parameters for predicting OS. There appeared to be no survival differences between menstrual cycle groups after stratification by lymph node status.
Conclusions: This prospective study showed a lack of prognostic value of timing at surgery in relation to the menstrual period or to estrogen and progesterone levels in premenopausal breast carcinoma. Conversely, high gonadotropin levels could predict OS independently of other prognostic factors.
(Copyright 2001 American Cancer Society.)